Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53

被引:15
作者
Chan, Justin M. [1 ,2 ]
Ho, Shirley H. [1 ,2 ]
Tai, Isabella T. [1 ,2 ]
机构
[1] Univ British Columbia, Div Gastroenterol, Vancouver, BC V5Z 1M9, Canada
[2] British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada
基金
加拿大健康研究院;
关键词
CELLS IN-VITRO; DNA-DAMAGE; ENDOTHELIAL-CELLS; V-JUN; CYCLE PROGRESSION; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; APOPTOSIS; SPARC; ARREST;
D O I
10.1093/carcin/bgq034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cellular senescence is another mechanism that can be exploited to achieve better chemosensitivity and greater tumor regression. Unlike apoptosis, cellular senescence can be induced at much lower concentrations of chemotherapy that are better tolerated by patients. We previously revealed that secreted protein acidic and rich in cysteine (SPARC), a matricellular protein, may function as a modulator of chemotherapy sensitivity by enhancing apoptosis. Here, we examine the effects of SPARC on cellular senescence in the presence of chemotherapy. Cellular senescence is induced only in sensitive colorectal cancer (CRC) cells with low concentrations of irinotecan (CPT-11). However, CPT-11-resistant cells exposed to endogenous or exogenous SPARC can also be triggered into cellular senescence. This induction is associated with higher levels of p16(INK4A) and phosphorylated p53. Knock down of p16(INK4A) reduces drug-induced senescence in all cells, but knock down and overexpression of p53 modulates senescence only in cells exposed to SPARC. Furthermore, treatment of mice with SPARC and CPT-11 leads to significantly increased cellular senescence and tumor regression. The chemosensitizing effects of SPARC in CRCs are, therefore, probably mediated in part by activating cellular senescence.
引用
收藏
页码:812 / 819
页数:8
相关论文
共 50 条
[1]   SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].
BAKER, SJ ;
MARKOWITZ, S ;
FEARON, ER ;
WILLSON, JKV ;
VOGELSTEIN, B .
SCIENCE, 1990, 249 (4971) :912-915
[2]   DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].
Bartkova, J ;
Horejsi, Z ;
Koed, K ;
Krämer, A ;
Tort, F ;
Zieger, K ;
Guldberg, P ;
Sehested, M ;
Nesland, JM ;
Lukas, C ;
Orntoft, T ;
Lukas, J ;
Bartek, J .
NATURE, 2005, 434 (7035) :864-870
[3]   p53 in signaling checkpoint arrest or apoptosis [J].
Bates, S ;
Vousden, KH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) :12-18
[4]   The signals and pathways activating cellular senescence [J].
Ben-Porath, I ;
Weinberg, RA .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (05) :961-976
[5]   TP53 status and response to chemotherapy in breast cancer [J].
Bertheau, Philippe ;
Espie, Marc ;
Turpin, Elisabeth ;
Lehmann, Jacqueline ;
Plassa, Louis-Francois ;
Varna, Mariana ;
Janin, Anne ;
de The, Hugues .
PATHOBIOLOGY, 2008, 75 (02) :132-139
[6]   Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth [J].
Bhonde, MR ;
Hanski, ML ;
Notter, M ;
Gillissen, BF ;
Daniel, PT ;
Zeitz, M ;
Hanski, C .
ONCOGENE, 2006, 25 (02) :165-175
[7]   Restoration of wild-type p53 function in human cancer: Relevance for tumor therapy [J].
Bossi, Gianluca ;
Sacchi, Ada .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2007, 29 (03) :272-284
[8]   v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3 [J].
Chamboredon, S ;
Briggs, J ;
Vial, E ;
Hurault, J ;
Galvagni, F ;
Oliviero, S ;
Bos, T ;
Castellazzi, M .
ONCOGENE, 2003, 22 (26) :4047-4061
[9]  
Chen J, 2008, J NEPHROL, V21, P337
[10]   SENESCENCE-DEPENDENT REGULATION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN HUMAN VASCULAR ENDOTHELIAL-CELLS [J].
COMI, P ;
CHIARAMONTE, R ;
MAIER, JAM .
EXPERIMENTAL CELL RESEARCH, 1995, 219 (01) :304-308